SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IMMULOGIC
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Lyle Abramowitz who wrote (34)5/10/1996 7:21:00 PM
From: Bhag Karamchandani   of 305
 
In an optimistic scenario IMUL undertakes another Phase III trial- set back 6 month and a few million dollars. In a pessimistic scenario IMUL gets mixed results again. To design 'double blind' tests with patients continuing to take their regular antihistamine is like testing medication for pain relief while continuing to allow participants to take aspirin. Makes it much harder to establish efficacy of the new drug. Don't you think??
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News